Antidiabetics

Active ingredients

Insulins substitute for endogenous insulin:

  • Human insulin
  • Insulin analogues

Biguanides reduce hepatic glucose formation:

Sulfonylureas promote insulin secretion from beta cells:

Glinides promote insulin secretion from beta cells:

  • Repaglinide (NovoNorm, generic).
  • Nateglinide (Starlix)

Glitazones decrease peripheral insulin resistance:

Alpha-glucosidase inhibitors inhibit the digestion of carbohydrates:

  • Acarbose (Glucobay)
  • Miglitol (Diastabol, out of commerce).

Gliptins (dipeptidyl peptidase-4 inhibitors) increase insulin secretion, decrease glucagon secretion, and increase satiety:

  • Alogliptin (Vipidia).
  • Linagliptin (Trajenta)
  • Saxagliptin (Onglyza)
  • Sitagliptin (Januvia)
  • Vildagliptin (Galvus)

GLP-1 receptor agonists increase insulin secretion, decrease glucagon secretion, and increase satiety:

  • Albiglutide (Eperzan).
  • Dulaglutide (Trulicity)
  • Exenatide (Byetta, Bydureon)
  • Liraglutide (Victoza, Saxenda)
  • Lixisenatide (Lyxumia)

SGLT2 inhibitors promote renal excretion of glucose by inhibiting reabsorption via the SGLT2 transporter:

  • Canagliflozin (Invokana).
  • Dapagliflozin (Forxiga)
  • Empagliflozin (Jardiance)
  • Ipragliflozin (Suglat, first approved in 2014 in Japan).
  • Tofogliflozin (Apleway, Deberza, initial approval 2014 in Japan).

Amylinomimetics decrease glucagon secretion:

  • Pramlintide (not commercially available in many countries).

Concomitant medication for diabetes:

  • Antihypertensives
  • Antiplatelet agents: acetylsalicylic acid
  • Lipid-lowering agents
  • Antiadiposita

Herbal antidiabetics:

  • Goat’s rue (controversial)
  • Guar
  • Cinnamon (controversial)
  • Bilberry (retinopathy, microangiopathy).
  • Bitter melon (controversial)